These are briefly discussed below
It must not be used for any form of clinical or diagnostic application
As described in the CY 2023 PFS final rule (87 FR 70072) and the FY 2023 IPPS/LTCH PPS final rule (87 FR 49338), we currently define active engagement as when the MIPS eligible clinician, eligible hospital, or CAH is in the process of moving towards sending production data to a PHA or clinical data registry (CDR), or is sending production data to a PHA or CDR
Ongoing studies continue to examine extracellular matrix remodeling, angiogenic signaling, immune regulation, epithelial barrier function, cell migration, and tissue homeostasis
Identifying low testosterone is only the first stepunderstanding why its low, how it interacts with other hormones, and how to optimize it safely requires advanced diagnostic testing